Anthony Gordon

    Home / Anthony Gordon

Anthony Gordon

ACG2013 copyDr Anthony Gordon

– Clinical Senior Lecturer, Imperial College London

– Director of Research, Intensive Care Foundation

– Lead for Emergency and Critical Care Medicine therapeutic group within the Imperial Clinical trials Unit

– NIHR Clinician Scientist

Phone: 020 3313 0657

Email:  anthony.gordon@imperial.ac.uk

Address: 11N ICU, Charing Cross Hospital, Fulham Palace Road, London W6 8RF

Region: NW London

Research type: Clinical trials and translational research

Research Interests:

  1. Sepsis – clinical trials
  2. Sepsis biomarkers – genetics and metabonomics
  3. Innate immune response

Key Techniques: Clinical trials and statistics

Laboratory: various immunological techniques including flow cytometry, ELISA; NMR and Mass spectrometry

Keywords:  Sepsis; shock; infection; clinical trials; genetics; metabonomics

Funding: NIHR-EME; NIHR-RfPB; Intensive Care Foundation

Collaborations: UK Critical Care Genomics Group, SuDDICU investigators

Selected Publications:

  1. Gordon AC et al. Protocol for a randomised controlled trial of Vasopressin versus Noradrenaline as Initial therapy in Septic sHock (VANISH). BMJopen 2014; 4: 
e005866. doi:10.1136/ bmjopen-2014-005866
  2. Orme RMet alAn efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial.Trials 2014; 15: 199 doi:10.1186/1745-6215-15-199
  3. Gordon AC et al. The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Critical Care Medicine 2014; 42(6); 1325-1333
  4.     Walden A et al. Patients with community acquired pneumonia admitted to European Intensive Care Units: an epidemiological survey of the GenOSept cohort. Critical Care 2014; 18(2): R58
  5.  Tridente A et al. Patients with faecal peritonitis admitted to European Intensive Care Units: an epidemiological survey of the GenOSept cohort. Intensive Care Medicine 2014; 40(2): 202-10
  6.  Dunning J et al. Open source clinical science for emerging infections. Lancet Infectious Diseases 2014; 14(1): 8-9.
  7.  Gordon AC et al. The cardiopulmonary effects of vasopressin compared to norepinephrine in septic shock. Chest 2012; 142(3): 593-605
  8.  Gordon AC, et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Medicine 2010; 36 (1) 83-91
  9.  Russell JA et al. Interaction of vasopressin infusion, corticosteroid treatment and mortality of septic shock. Critical Care Medicine2009; 37 (3) 811-818
  10.  Wurfel MM et al. Toll-like Receptor 1 Polymorphisms Affect Innate Immune Responses and Outcomes in Sepsis. American Journal of Respiratory and Critical Care Medicine2008; 178 (7) 710-720
  11.  Russell JA, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. The New England Journal of Medicine2008; 358 (9) 877-887.
  12.  Gordon AC, et al. Mannose-binding lectin polymorphisms in severe sepsis; relationship to levels, incidence and outcome Shock 2006; 25 (1) 88-93.
  13.  Gordon AC et al. TNF and TNFR polymorphisms in severe sepsis and septic shock: a prospective multicentre study. Genes and Immunity 2004; 5 (8) 631-640